Medicine
Soliqua 100/33 100 units/33 mcg per mL injection
Soliqua 100/33 100 units/33 mcg per mL injection is a prescription medicine containing Insulin glargine and Lixisenatide for subcutaneous use, marketed by Sanofi-Aventis, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Prior to first use, SOLIQUA 100/33 pen should be stored in a refrigerator…
Key facts
- Active ingredient (INN)
- Insulin glargine and Lixisenatide
- Brand
- Soliqua 100/33
- Strength
- 100 units/33 mcg per mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe, 5 syringes
- Marketing authorisation holder
- Sanofi-Aventis
- Manufacturer
- Sanofi-Aventis
- Origin register
- US FDA, United States
- Storage
- Prior to first use, SOLIQUA 100/33 pen should be stored in a refrigerator, 36°F–46°F (2°C–8°C). Do not freeze. After first use, store at room temperature up to 77°F (25°C). Protect from light. Replace the pen cap after each use to protect from light. Remove the needle after each injection and store the SOLIQUA 100/33 pen without a needle attached.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10AE54 Insulin glargine and Lixisenatide
- HS code (indicative)
- 3004.31Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 November 2016
- Identifiers
- RxCUI 1858995, 1859000DailyMed set ID 4bba538b-cf7c-4310-ae8f-cb711ed21bccNDC 0024-5761Application BLA208673
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe in 1 carton / 3 mL in 1 syringe | 0024-5761-01 | Sanofi-Aventis | 21 November 2016 |
| 5 syringe in 1 carton / 3 mL in 1 syringe | 0024-5761-05 | Sanofi-Aventis | 21 November 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Insulin glargine and Lixisenatide is a fixed-dose combination of a GLP-1 receptor agonist and an insulin analog. It is available as injection for subcutaneous use. MedsAcross supplies Insulin glargine and Lixisenatide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Insulin glargine and LixisenatideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Soliqua 100/33 prescribing information (Sanofi-Aventis) · U.S. National Library of Medicine, DailyMed
- Suliqua: European public assessment report (EPAR) · European Medicines Agency
Need Soliqua 100/33 100 units/33 mcg per mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.